1-20 of 37
Eric P. Winer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang, Alyssa Pereslete, Liangge Hsu, Pamela J. DiPiro, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S. Raghavendra, Maria Gule-Monroe, Rashmi K. Murthy, Eric P. Winer, Carey K. Anders, Jean J. Zhao, Nancy U. Lin
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 174–182.
https://doi.org/10.1158/1078-0432.CCR-22-1138
Published: 04 January 2023
View article titled, Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Open the PDF for Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

Junko Tsuji, Tianyu Li, Albert Grinshpun, Tim Coorens, Douglas Russo, Leilani Anderson, Rebecca Rees, Agostina Nardone, Candace Patterson, Niall J. Lennon, Carrie Cibulskis, Ignaty Leshchiner, Nabihah Tayob, Sara M. Tolaney, Nadine Tung, Donald P. McDonnell, Ian E. Krop, Eric P. Winer, Chip Stewart, Gad Getz, Rinath Jeselsohn
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5066–5078.
https://doi.org/10.1158/1078-0432.CCR-22-2305
Published: 01 December 2022
View article titled, Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Open the PDF for Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Felipe Batalini, Doga C. Gulhan, Victor Mao, Antuan Tran, Madeline Polak, Niya Xiong, Nabihah Tayob, Nadine M. Tung, Eric P. Winer, Erica L. Mayer, Stian Knappskog, Per E. Lønning, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos, David B. Solit, Helen Won, Hans P. Eikesdal, Peter J. Park, Gerburg M. Wulf
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4714–4723.
https://doi.org/10.1158/1078-0432.CCR-22-0749
Published: 01 November 2022
View article titled, Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Open the PDF for Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers in another window
Includes: Supplementary data
Journal Articles

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1493–1499.
https://doi.org/10.1158/1078-0432.CCR-21-3045
Published: 14 April 2022
View article titled, Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Open the PDF for Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Tanya E. Keenan, Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae Davis, Ricardo Pastorello, Rie K. Tahara, Leilani Anderson, Jake Conway, Meng X. He, Erin Shannon, Robert E. Godin, Peter K. Sorger, Alan D'Andrea, Beth Overmoyer, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Geoffrey I. Shapiro, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 983–991.
https://doi.org/10.1158/1078-0432.CCR-20-3089
Published: 15 February 2021
View article titled, Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Open the PDF for Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Characterization of de novo Metastatic Breast Cancer

Ana C. Garrido-Castro, Liam F. Spurr, Melissa E. Hughes, Yvonne Y. Li, Andrew D. Cherniack, Priti Kumari, Maxwell R. Lloyd, Brittany Bychkovsky, Romualdo Barroso-Sousa, Simona Di Lascio, Esha Jain, Janet Files, Ayesha Mohammed-Abreu, Max Krevalin, Colin MacKichan, William T. Barry, Hao Guo, Daniel Xia, Ethan Cerami, Barrett J. Rollins, Laura E. MacConaill, Neal I. Lindeman, Ian E. Krop, Bruce E. Johnson, Nikhil Wagle, Eric P. Winer, Deborah A. Dillon, Nancy U. Lin
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1105–1118.
https://doi.org/10.1158/1078-0432.CCR-20-1720
Published: 15 February 2021
View article titled, Genomic Characterization of <em>de novo</em> Metastatic Breast Cancer
Open the PDF for Genomic Characterization of <em>de novo</em> Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

Pingping Mao, Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco, Pedro Exman, Seth A. Wander, Adrienne G. Waks, Utthara Nayar, Jon Chung, Samuel Freeman, Orit Rozenblatt-Rosen, Vincent A. Miller, Federica Piccioni, David E. Root, Aviv Regev, Eric P. Winer, Nancy U. Lin, Nikhil Wagle
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5974–5989.
https://doi.org/10.1158/1078-0432.CCR-19-3958
Published: 13 November 2020
View article titled, Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer
Open the PDF for Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik J. Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura Dickler, Ann Partridge, Lisa A. Carey, Eric P. Winer, Hope S. Rugo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4911–4920.
https://doi.org/10.1158/1078-0432.CCR-20-1329
Published: 15 September 2020
View article titled, Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab
Open the PDF for Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab in another window
Includes: Supplementary data
Journal Articles

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Heather A. Parsons, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, Christopher C. Lo, Tianyu Li, Mark Fleharty, Gregory J. Kirkner, Denisse Rotem, Ofir Cohen, Fangyan Yu, Mariana Fitarelli-Kiehl, Ka Wai Leong, Melissa E. Hughes, Shoshana M. Rosenberg, Laura C. Collins, Kathy D. Miller, Brendan Blumenstiel, Lorenzo Trippa, Carrie Cibulskis, Donna S. Neuberg, Matthew DeFelice, Samuel S. Freeman, Niall J. Lennon, Nikhil Wagle, Gavin Ha, Daniel G. Stover, Atish D. Choudhury, Gad Getz, Eric P. Winer, Matthew Meyerson, Nancy U. Lin, Ian Krop, J. Christopher Love, G. Mike Makrigiorgos, Ann H. Partridge, Erica L. Mayer, Todd R. Golub, Viktor A. Adalsteinsson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2556–2564.
https://doi.org/10.1158/1078-0432.CCR-19-3005
Published: 01 June 2020
View article titled, Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Open the PDF for Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

Romualdo Barroso-Sousa, Tanya E. Keenan, Sonia Pernas, Pedro Exman, Esha Jain, Ana C. Garrido-Castro, Melissa Hughes, Brittany Bychkovsky, Renato Umeton, Janet L. Files, Neal I. Lindeman, Laura E. MacConaill, F. Stephen Hodi, Ian E. Krop, Deborah Dillon, Eric P. Winer, Nikhil Wagle, Nancy U. Lin, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2565–2572.
https://doi.org/10.1158/1078-0432.CCR-19-3507
Published: 01 June 2020
View article titled, Tumor Mutational Burden and <em>PTEN</em> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Open the PDF for Tumor Mutational Burden and <em>PTEN</em> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study

Jennifer A. Ligibel, Deborah Dillon, Anita Giobbie-Hurder, Anne McTiernan, Elizabeth Frank, MacIntosh Cornwell, Matthew Pun, Nancy Campbell, Ryan J.O. Dowling, Martin C. Chang, Sara Tolaney, Anees B. Chagpar, Rachel L. Yung, Rachel A. Freedman, Laura S. Dominici, Mehra Golshan, Esther Rhei, Krishan Taneja, Ying Huang, Myles Brown, Eric P. Winer, Rinath Jeselsohn, Melinda L. Irwin
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5398–5406.
https://doi.org/10.1158/1078-0432.CCR-18-3143
Published: 03 September 2019
View article titled, Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study
Open the PDF for Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study in another window
Includes: Supplementary data
Journal Articles

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Adrienne G. Waks, Daniel G. Stover, Jennifer L. Guerriero, Deborah Dillon, William T. Barry, Evisa Gjini, Christina Hartl, Wesley Lo, Jennifer Savoie, Jane Brock, Robert Wesolowski, Zaibo Li, Adrienne Damicis, Anne V. Philips, Yun Wu, Fei Yang, Amy Sullivan, Patrick Danaher, Heather Ann Brauer, Wafa Osmani, Mikel Lipschitz, Katherine A. Hoadley, Michael Goldberg, Charles M. Perou, Scott Rodig, Eric P. Winer, Ian E. Krop, Elizabeth A. Mittendorf, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4644–4655.
https://doi.org/10.1158/1078-0432.CCR-19-0173
Published: 01 August 2019
View article titled, The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Open the PDF for The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy in another window
Includes: Supplementary data
Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 2975–2987.
https://doi.org/10.1158/1078-0432.CCR-18-3160
Published: 15 May 2019
View article titled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Open the PDF for A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Terry M. Hyslop, Brandelyn N. Pitcher, Matthew G. Soloway, Patricia A. Spears, Lynn N. Henry, Sara Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay N. Harris, Donald A. Berry, Elaine R. Mardis, Eric P. Winer, Clifford A. Hudis, Lisa A. Carey, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5292–5304.
https://doi.org/10.1158/1078-0432.CCR-17-3431
Published: 01 November 2018
View article titled, Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?

Sheheryar Kabraji, Jing Ni, Nancy U. Lin, Shaozhen Xie, Eric P. Winer, Jean J. Zhao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1795–1804.
https://doi.org/10.1158/1078-0432.CCR-17-3351
Published: 12 April 2018
View article titled, Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Open the PDF for Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? in another window
Journal Articles

Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER

Zhigang C. Wang, Nicolai Juul Birkbak, William T. Barry, Thomas M. Roberts, Eric P. Winer, J Dirk Iglehart, Ursula A. Matulonis, S. Percy Ivy, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-112.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-112
Published: 31 May 2017
View article titled, Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER
Journal Articles

The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis

Daniel G. Stover, Jonathan L. Coloff, William T. Barry, Joan S. Brugge, Eric P. Winer, Laura M. Selfors
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6039–6050.
https://doi.org/10.1158/1078-0432.CCR-16-0471
Published: 15 December 2016
View article titled, The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Open the PDF for The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis in another window
Includes: Supplementary data
Journal Articles

TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer

Rinath Jeselsohn, William T. Barry, Ilenia Migliaccio, Chiara Biagioni, Jin Zhao, Jonas De Tribolet-Hardy, Cristina Guarducci, Martina Bonechi, Naomi Laing, Eric P. Winer, Myles Brown, Angelo Di Leo, Luca Malorni
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5755–5764.
https://doi.org/10.1158/1078-0432.CCR-16-0148
Published: 30 November 2016
View article titled, TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Open the PDF for TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid, Bryan Hennessy, Gordon B. Mills, Kristin C. Jensen, Zoltan Szallasi, William T. Barry, Eric P. Winer, Nadine M. Tung, Steven J. Isakoff, Paula D. Ryan, April Greene-Colozzi, Alexander Gutin, Zaina Sangale, Diana Iliev, Chris Neff, Victor Abkevich, Joshua T. Jones, Jerry S. Lanchbury, Anne-Renee Hartman, Judy E. Garber, James M. Ford, Daniel P. Silver, Andrea L. Richardson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (15): 3764–3773.
https://doi.org/10.1158/1078-0432.CCR-15-2477
Published: 31 July 2016
View article titled, Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Open the PDF for Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data